

# Repeatability of airway resistance measurements made using the interrupter technique

E Y Chan, P D Bridge, I Dundas, C S Pao, M J R Healy, S A McKenzie

Thorax 2003;58:344–347

See end of article for authors' affiliations

Correspondence to:  
Dr S A McKenzie,  
Department of Respiratory  
Paediatrics, Fielden House,  
The Royal London Hospital,  
London E1 1BB, UK;  
S.A.McKenzie@qmul.ac.uk

Revised version received  
9 September 2002  
Accepted for publication  
23 November 2002

**Background:** To be able to interpret any measurement, its repeatability should be known. This study reports the repeatability of airway resistance measurements using the interrupter technique (Rint) in children with and without respiratory symptoms.

**Methods:** Children aged 2–10 years who were healthy, had persistent isolated cough, or who had previous wheeze were studied. On the same occasion, three Rint measurements were made 15 minutes apart, before and after placebo and salbutamol given in random order. Results from those given placebo first were analysed for within-occasion repeatability. Between-occasion repeatability measurements were made 2–20 weeks apart (median 3 weeks).

**Results:** For 85 pairs of measurements before and after placebo the limits of agreement were 20% expected resistance and were unaffected by age or health status. The change in resistance following bronchodilator in one of 18 healthy children, 12 of 28 with cough, and 22 of 39 with wheeze exceeded this threshold. For between-occasion measurements the limits of agreement were 32% in 72 healthy subjects, 49% in 57 with cough, and 53% in 95 with previous wheeze.

**Conclusion:** The measurement of airways resistance by the interrupter technique is clinically meaningful when change following an intervention such as the administration of bronchodilator is greater than its within-occasion repeatability. Between-occasion repeatability is too poor to judge change confidently.

To interpret any measurement of lung function properly the precision of the measurement should be known in healthy subjects and in those with respiratory complaints. This is usually described by the coefficient of variation. To evaluate whether change following an intervention—such as the response to the inhalation of a bronchodilator or bronchial challenge—is likely to be “true”, the within-occasion repeatability of a lung function test should be known.<sup>1</sup> For lung function testing it is assumed that within-occasion repeatability measures the stability of the measuring instrument<sup>2</sup> and the consistency of the technical expertise of the subject undertaking the test. Between-occasion repeatability is influenced by biological variation in lung function in addition to the stability of the measuring instrument and the technical consistency of the subject. These measurements are important for the clinician who is interested in assessing change in the *individual*, and there are a number of statistical descriptions of the repeatability of a measurement. These methods of describing change are different from the assessment of *group* changes which are of interest to the researcher and epidemiologist.

A study was undertaken to determine the within-occasion and between-occasion repeatability of airway resistance measured by the interrupter technique (Rint) in children with no respiratory symptoms, those with persistent isolated cough, and those with previous wheeze. Children with cough and those with a history of wheeze are often referred to a respiratory paediatrician for assessment of their symptoms. Our previous work has suggested that bronchodilator responsiveness in “coughers” is intermediate between controls and “wheezers”.<sup>3,4</sup> We hypothesised that the repeatability in previous wheezers would be poorer than in controls and that coughers would be intermediate. Within-occasion repeatability was compared with the change following an intervention—namely, the response to a bronchodilator. How between-occasion repeatability measured with Rint compared with other methods and with changes following interventions was examined.

## METHODS

Children aged 2–10 years were recruited from local schools (controls) and from ambulatory and outpatient clinics (coughers and wheezers). Within-occasion repeatability described in absolute values of Rint (kPa/L.s) has been reported previously in children aged 2–5 years,<sup>5</sup> but measurements related to normative data are reanalysed here together with those of older children to examine the effect of age over a wide range and the effect of health status on repeatability.

The children comprised three groups: (1) those with no history of respiratory symptoms by accepted criteria<sup>6</sup>; (2) those with persistent isolated cough (who had had cough for more than 3 weeks or on three occasions in the previous 6 months); and (3) those with doctor observed wheeze in the previous 4–6 weeks but who were not wheezy at the time of testing. No child was on long term treatment. Children with upper respiratory tract infections in the previous 3 weeks were excluded.

Rint was measured as previously described<sup>5</sup> in the expiratory phase of tidal breathing using a Micromedical device. If the coefficient of variation of the values contributing to each measurement was more than 20%, the measurement was excluded. During the same laboratory visit three measurements were made 15 minutes apart, before and after placebo and salbutamol 400 µg given in random order to which the observer was blind. Both were given using a spacer device and inhaled during tidal breathing. Only measurements of those who received placebo first were analysed.

For between-occasion repeatability, those children who had successfully undertaken measurement of Rint but not necessarily the 15 minute repeatability testing and were willing to return had a further test within the following 20 weeks. We are not able to describe those children whose parents did not give permission for them to be studied as we could not obtain the necessary information, but we have no reason to believe that subjects whose parents agreed to their participation were any different from those whose parents did not. The coughers returned because they were still coughing. Measurements

**Table 1** Repeatability of airway resistance measured by the interrupter technique (R<sub>int</sub>)

	Within-occasion	Between-occasion		
	All groups (n=85)	Controls (n=72)	Coughers (n=57)	Wheezers (n=95)
Age (years)				
Median (range)	4.8 (2.0–9.9)	6.2 (2.2–9.8)*	4.7 (2.0–9.4)*	4.4 (2.0–9.5)*
Mean difference†				
% expected	–0.4%	4.3%	4.4%	5.2%
95% CI	(–0.1 to +0.1)	(+0.6 to +8.0)	(–2.1 to +11)	(–0.1 to +10.5)
p value	0.46	0.02	0.18	0.05
CV	6.5%	11%	16%	15%
ICC	0.97	0.75	0.56	0.66
Limits of agreement				
% expected	20%	32%	49%	52%
z scores	0.87	1.38	1.88	1.92
Absolute values (kPa/l.s)	0.17	0.23	0.38	0.44

CV=coefficient of variation; ICC= intraclass correlation coefficient.

\*Age at first visit.

†Mean difference for (a) within occasion = pre – post placebo; (b) between occasion = visit 1 – visit 2.

were made at a similar time of day either in the routine lung function laboratory (essentially an ambulatory setting<sup>5</sup>) or in local schools. Both the researcher and subject were blinded to the results of the first measurement.

The local ethics committee approved the project and parents and children old enough to understand the project gave informed consent for the study.

### Data analysis

Data were analysed using Nanostat (AlphaBridge Ltd, London, UK). Using normative data from the local population,<sup>7</sup> measurements were expressed as the percentage expected for age because between-occasion measurements could be up to 20 weeks apart. For our data, age predicts R<sub>int</sub> slightly better than height. The equation used was:

$$\log_{10} R_{int} = 0.116 - 0.0396 \times \text{age}$$

Repeatability was described as follows:

(1) The limits of agreement of two measurements = 2 standard deviations (SD) of the differences between measurements. This was calculated for measurements (percentage expected) before and after placebo for the within-occasion estimation and similarly for paired baseline between-occasion measurements. So that the results could be compared with some of those published, the limits of agreement of unadjusted values (kPa/l.s) are also quoted. Change expressed as a multiple of the SD of the mean value for age (z score) is also presented. If a difference between two measurements lies between the limits of agreement, it cannot be said with 95% certainty that there has been “true” change. If a difference lies above these limits, such a difference cannot be explained by measurement error alone.

(2) The coefficient of variation of a measurement = (SD of the differences between measurements/√2)/mean of the measurements. The coefficient of variation of a measurement describes the precision of the measurement related to its mean value.

(3) The intraclass correlation coefficient =  $1 - ((\text{SD differences between measurements}/\sqrt{2})^2 / (\text{SD of the measurements}^2))$ . The intraclass correlation coefficient describes how well pairs of measurements correlate.

The relationship of the limits of agreement with health status was examined by calculating the F ratios for the variances of the three groups (controls, coughers, and wheezers). This statistical test examines whether there is a significant difference between the variances of the groups. To examine the effect of age on the variance, the absolute residuals of all data were regressed on age and group.

## RESULTS

Fifty five percent of the study participants were boys; 52% were Bangladeshi, 15% Afro-Caribbean, and 33% white British. Z scores for height were as previously published.<sup>7</sup>

### Within-occasion repeatability

Of 174 children who agreed to undertake reversibility testing, 85 (46 aged 2–5 years and 39 aged >5–10 years) received the placebo first. There were 18 healthy children, 28 coughers, and 39 wheezers. The measurements of repeatability are shown in table 1. There was no relationship between the width of the limits of agreement and age ( $p=0.68$ ) and health status (healthy *v* coughers, F ratio=1.22,  $p=0.31$ ; healthy *v* wheezers, F ratio=1.1,  $p=0.38$ ). The limits of agreement of the two measurements were 20% of expected R<sub>int</sub> for age.

Following administration of bronchodilator, the median fall in R<sub>int</sub> was 8.5% expected (interquartile range 3.5–12.7%) in the healthy children, 17.1% expected (interquartile range 5.9–28.3%) in coughers, and 22.6% expected (interquartile range 6.3–44.9%) in wheezers. Bronchodilator responsiveness in healthy children differed from that in both coughers ( $p=0.03$ ) and wheezers ( $p=0.01$ ). One of the 18 healthy children, 12 of the 28 coughers, and 22 of the 39 wheezers responded to salbutamol with a change of over 20% expected in R<sub>int</sub> for age, the within-occasion limits of agreement.

### Between-occasion repeatability

In 224 children who agreed to R<sub>int</sub> measurements but not necessarily to the within-occasion study, the median time between measurements was 3 weeks (range 2–20). Their age ranges, health status, and measurements of repeatability are shown in table 1.

The F ratio for healthy children *v* coughers was 2.13 ( $p=0.001$ ), for healthy children *v* wheezers was 2.64 ( $p<0.0001$ ), and for coughers *v* wheezers was 1.23 ( $p=0.18$ ). Multiregression analysis showed that, when health status was taken into account, the increase in standard deviation/year of age between ages 2 and 10 was no more than 2.3% ( $p=0.02$ ).

Differences between tests before and after placebo were unrelated to their means ( $r^2=0.003$ ), which suggests that there was no “regression to the mean” for within-occasion measurements. There was no relationship between measurement differences and the time between tests ( $r^2=0.05$ ), suggesting that tests repeated within a short time were no more in agreement than those within a longer time.

## DISCUSSION

This study has shown that within-occasion repeatability, as described by the limits of agreement, is 20% of expected R<sub>int</sub>

for age and is similar for healthy children, coughers and wheezers. This means that we cannot be 95% confident that any difference of less than 20% expected between two measurements made on the same occasion is true change. This figure must be interpreted together with changes that are likely to be encountered. In this study Rint changed by more than 20% expected in response to a bronchodilator in only one of 18 healthy children. As might have been predicted, in previous wheezers the response exceeded 20% expected in significantly more children. (For differences less than this, where differences in healthy and wheezy children in response to an intervention overlap, the interpretation of the difference is assisted by a receiver-operator characteristic curve.<sup>3</sup> Discussion of this is outside the scope of this paper.) Coughers were in an intermediate position. Those with persistent wheezing or who were wheezy at the time of testing might be expected to have an even greater response.

For between-occasion repeatability, the limits of agreement for healthy children were 32% expected but, for stable children who had been wheezing within the previous 6 weeks, this rose to 52% expected. As a hallmark of asthma is bronchial lability, this is not surprising. However, this observation could be of diagnostic interest. If a child's repeat measurement is outside the limits of agreement of differences in healthy children, then that child could be classified with those who are either coughers or wheezers. Children with isolated cough take an intermediate position. These results would fit in with our previous observations that bronchial lability measured by bronchodilator responsiveness in coughers is intermediate between that in controls and in wheezers.<sup>3,4</sup> Unexpectedly, there was a very small increase in standard deviation of the differences between measurements with age. Repeatability would be expected to be poorer in young children. This small increase is unlikely to be of clinical importance. There is also a small increase in the mean difference between occasions, but only about 10% of limits of agreement. We are unable to explain this as the equipment was the same between occasions and operators had undertaken acceptable interrater reliability measurements before embarking on the project.<sup>8</sup>

We have also presented intraclass correlation coefficients (ICC) for within-occasion and between-occasion repeatability, as these are sometimes quoted in the results of other studies. In this study the ICC for within-occasion repeatability of Rint was 0.97, suggesting nearly perfect correlation. The limits of agreement were 20% expected. For measurements of repeatability the limits of agreement are much more informative.

Clinicians often request lung function testing to monitor disease progress or the response to treatment in an individual. However, with Rint it seems that change between two occasions cannot be measured with confidence. In a controlled trial of the effect of corticosteroids on Rint in preschool children, those with positive skin prick test results were shown to benefit significantly after 6 weeks of treatment. Mean Rint improved by 16% for the group.<sup>9</sup> However, the between-occasion repeatability of the measurement described in the present study suggests that, in the *individual*, this magnitude of change could not be detected with 95% confidence.

By comparison, the within-occasion coefficient of variation of forced expiratory volume in 1 second (FEV<sub>1</sub>) in a group of healthy and asthmatic children is 4.3%,<sup>10</sup> which means that the limits of agreement for change will be about 12%. (These figures are based on absolute values and not percentage expected.) Bronchodilator responsiveness measured using spirometric tests is considered positive if there is a change in FEV<sub>1</sub> of 12%.<sup>11</sup> However, for between-occasion repeatability the coefficient of variation of FEV<sub>1</sub> is 8.3% and the derived limits of agreement rise to 23%.<sup>10</sup> In a clinical trial of the effect of inhaled corticosteroids, FEV<sub>1</sub> changed by a mean of 5% over 6 weeks.<sup>12</sup> This change would not be detected in the *individual* with confidence using spirometric tests.

For precise assessment of repeatability of any measurement (based on the 95% confidence limits of the estimate of

variance), a minimum of 50 pairs of measurements is needed.<sup>13</sup> Estimates of repeatability of measurements of airway resistance have been made by others using the interrupter technique with fewer measurements and using devices with different specifications.<sup>14-17</sup> Nevertheless, our measurements of coefficient of variation and intraclass correlation coefficients are comparable with those published. Ducharme and Davis<sup>18</sup> measured airway resistance using the forced oscillation technique in 114 asthmatic children aged 3-17 years and obtained a within-occasion coefficient of variation of 9%. There are no between-occasion studies of adequate numbers of the repeatability of Rint, resistance measured using the forced oscillation technique, or resistance measured by plethysmography (Raw).

Van Noord *et al*<sup>19</sup> measured Raw and FEV<sub>1</sub> on the same occasion in a group of asthmatic adults. Three measurements of Raw were followed by three measurements of FEV<sub>1</sub>, from which were calculated the coefficients of variation of each and the limits of agreement derived (coefficient of variation  $\times 2\sqrt{2}$ ). The limits of agreement for FEV<sub>1</sub> were 13% and for Raw were 21%. Using these "thresholds", a response to bronchodilator was demonstrated in more subjects using resistance than using FEV<sub>1</sub>. Thus, although the resistance measurement seems to be more poorly repeatable, it is better for measuring change, at least in response to bronchodilators. A comparison of Rint, Raw, and FEV<sub>1</sub> in children has also shown that the coefficient of variation for FEV<sub>1</sub> is smaller than either Rint or Raw. However, measurements following challenge testing with methacholine found a larger change with Raw than the others when change was expressed as multiples of baseline standard deviation.<sup>15</sup> The changes in Rint and FEV<sub>1</sub> expressed in the same way were similar. Thus, although the repeatability of FEV<sub>1</sub> appears better than that of resistance measurements, the change in response to challenge is detected as well or better by resistance measurements. How changes in resistance measurements compare with a change in FEV<sub>1</sub> in children in response to a bronchodilator is not known.

In summary, the limits of agreement for the measurement of Rint seem wide. When we consider the change expected following an intervention where an immediate response is expected, such as that following bronchodilator inhalation, the fall in Rint is more likely to be in excess of these limits in children with persistent isolated cough and in previously wheezy children. For between-occasion measurements, the limits of agreement are too wide for change in the individual to be judged with confidence, as is the case for between-occasion repeatability of FEV<sub>1</sub>.

## ACKNOWLEDGEMENT

The authors are grateful to the National Asthma Campaign who funded this study.

## Authors' affiliations

**E Y Chan, P D Bridge, I Dundas, C S Pao, S A McKenzie**, Department of Respiratory Paediatrics, Fielden House, The Royal London Hospital, Barts and The London NHS Trust, London E1 1BB, UK  
**M J R Healy**, Department of Mathematics, Institute of Education, London WC1H 0AL, UK

## REFERENCES

- Hopkins WG. Measures of reliability in sports medicine and science. *Sports Med* 2000;**30**:1-15.
- Chinn S. Statistics in respiratory medicine. 2. Repeatability and method comparison. *Thorax* 1991;**46**:454-6.
- McKenzie SA, Bridge PD, Healy MJ. Airway resistance and atopy in preschool children with wheeze and cough. *Eur Respir J* 2000;**15**:833-8.
- McKenzie SA, Mylonopoulou M, Bridge PD. Bronchodilator responsiveness and atopy in 5-10-year-old coughers. *Eur Respir J* 2001;**18**:977-81.
- Bridge PD, Ranganathan S, McKenzie SA. The measurement of airway resistance using the interrupter technique (Rint) in pre-school children in the ambulatory setting. *Eur Respir J* 1999;**13**:792-6.

- 6 **Quanjer PH**, Stocks J, Polgar G, *et al.* Compilation of reference values for lung function measurements in children. *Eur Respir J Suppl* 1989;**4**:184–261S.
- 7 **McKenzie SA**, Chan E, Dundas I, *et al.* Airway resistance measured by the interrupter technique: normative data for 2–10 year olds of three ethnicities. *Arch Dis Child* 2002;**87**:248–51.
- 8 **Pao CS**, Bridge PD, McKenzie SA. Not all laboratories are alike. *Eur Respir J* 2001;**17**:1054.
- 9 **Pao CS**, McKenzie SA. Randomized controlled trial of fluticasone in preschool children with intermittent wheeze. *Am J Respir Crit Care Med* 2002;**166**:945–9.
- 10 **Strachan DP**. Repeatability of ventilatory function measurements in a population survey of 7 year old children. *Thorax* 1989;**44**:474–9.
- 11 **American Thoracic Society**. Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991;**144**:1202–18.
- 12 **Gustafsson P**, Tsanakas J, Gold M, *et al.* Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. *Arch Dis Child* 1993;**69**:206–11.
- 13 **Kendall MG**, Stuart A. Exact sampling distributions. In: *The advanced theory of statistics*. London: Griffin, 1977.
- 14 **van Altena R**, Gimeno F. Respiratory resistance measured by flow-interruption in a normal population. *Respiration* 1994;**61**:249–54.
- 15 **Bisgaard H**, Klug B. Lung function measurement in awake young children. *Eur Respir J* 1995;**8**:2067–75.
- 16 **Merkus PJ**, Mijnsbergen JY, Hop WC, *et al.* Interrupter resistance in preschool children. Measurement characteristics and reference values. *Am J Respir Crit Care Med* 2001;**163**:1350–5.
- 17 **Lombardi E**, Sly PD, Concutelli G, *et al.* Reference values of interrupter respiratory resistance in healthy preschool white children. *Thorax* 2001;**56**:691–5.
- 18 **Ducharme FM**, Davis GM. Measurement of respiratory resistance in the emergency department: feasibility in young children with acute asthma. *Chest* 1997;**111**:1519–25.
- 19 **Van Noord JA**, Smeets J, Clement J, *et al.* Assessment of reversibility of airflow obstruction. *Am J Respir Crit Care Med* 1994;**150**:551–4.

## LUNG ALERT .....

### Community based outpatient treatment of multidrug-resistant tuberculosis

▲ Mitnick C, Bayona J, Palacios E, *et al.* Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. *N Engl J Med* 2003;**348**:119–28

Treatment for multidrug-resistant tuberculosis (MDR-TB) is virtually non-existent in developing countries because of limited resources and infrastructure. This study assesses treatment feasibility and identifies predictors of poor outcome in patients receiving community based outpatient treatment for MDR-TB in a poor section of Lima. Seventy five patients (median age 27 years, one seropositive for HIV) with longstanding disease had received a median of three previous anti-TB regimens and harboured highly resistant strains (resistant to a median of six drugs). Of 66 patients who completed  $\geq 4$  months of individualised regimens, 55 (83%) were probably cured at the completion of treatment. Five of the 66 patients (8%) died while receiving treatment. Predictors of poor outcome (treatment failure or death) were low haematocrit (present in 12 patients, five of whom died) and low body mass index (present in 32, eight of whom died). The six most commonly used drugs were fluoroquinolones, cycloserine, PAS, ethionamide, amoxicillin-clavulanic acid, and capreomycin. The mean cost of treatment was £9565 per patient.

These results indicate that community based outpatient treatment of MDR-TB is feasible and can yield surprisingly high cure rates even in resource poor settings. The high costs of treatment will continue to be a major obstacle to implementation in developing countries. Further studies are needed to determine outcomes in developing countries with a high prevalence of HIV.

**K Dheda**

University College, London, UK;  
kdheda@hotmail.com